PRICED Act

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

D SchakowskySponsor

22 cosponsors · 21 D, 1 R

16 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

What it does: CRS summary · Introduced in House · Jun 20, 2019

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.

This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: PRICED Act

Also known as: Price Relief, Innovation, and Competition for Essential Drugs Act

Latest action (Jun 21, 2019): Referred to the Subcommittee on Health.

Policy area: Health · Origin: House · Introduced: Jun 20, 2019

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.